Approved and emerging Bruton’s tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Approved and emerging Bruton’s tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia

Published:2022-08-22 Issue:13 Volume:23 Page:1545-1557
ISSN:1465-6566
Container-title:Expert Opinion on Pharmacotherapy
language:en
Short-container-title:Expert Opinion on Pharmacotherapy

Author:

Hatashima Alycia¹,Karami Mehdi¹,Shadman Mazyar²³

Affiliation:

1. Department of Pharmacy, Fred Hutchinson Cancer Center, Seattle, WA, USA

2. Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA

3. Department of Medicine, Medical Oncology Division, University of Washington, Seattle, WA, USA

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14656566.2022.2113384

Reference77 articles.

1. Treatment of Chronic Lymphocytic Leukemia

2. The global burden and attributable risk factors of chronic lymphocytic leukemia in 204 countries and territories from 1990 to 2019: analysis based on the global burden of disease study 2019

3. Cancer statistics, 2022

4. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL

5. Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2023;Naunyn-Schmiedeberg's Archives of Pharmacology;2024-03-26

2. Bruton’s Tyrosine Kinase Inhibitors for Multiple Sclerosis Treatment;Neurologic Clinics;2024-02

3. A Phase II Study to Evaluate the Efficacy of Bortezomib in Combination with Thalidomide in Treatment-Naïve Waldenstrom Macroglobulinemia Patients;Cancer Research and Treatment;2023-09-25

4. Structure of BTK kinase domain with the second-generation inhibitors acalabrutinib and tirabrutinib;PLOS ONE;2023-08-31

5. Functional consequences of inhibition of Bruton's tyrosine kinase by ibrutinib in chronic lymphocytic leukemia;Hematological Oncology;2023-06

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3